BDBM322119 US10183913, Example 405::US11312688, Example 426

SMILES CNCc1cc(OCc2cc(Cl)ccc2F)n(CCC(C)OC)n1

InChI Key InChIKey=MHXQFPMLVSKHAC-UHFFFAOYSA-N

Data  6 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 322119   

TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322119(US10183913, Example 405 | US11312688, Example 426)
Affinity DataKi:  0.990nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322119(US10183913, Example 405 | US11312688, Example 426)
Affinity DataKi:  11nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322119(US10183913, Example 405 | US11312688, Example 426)
Affinity DataKi:  11nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322119(US10183913, Example 405 | US11312688, Example 426)
Affinity DataKi:  14nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322119(US10183913, Example 405 | US11312688, Example 426)
Affinity DataKi:  23nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322119(US10183913, Example 405 | US11312688, Example 426)
Affinity DataKi:  23nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent